S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
XTNT · Xtant Medical Holdings, Inc.
NYSE MKT LLC - BOATS Real Time Price • USD
$0.31
+0.01
(+3.10%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$0.31
$0.31
$0.31
52-WEEK RANGE
$0.31
$0.27
$0.95
What's happening
- XTNT is up 3.10% today, trading at $0.31. — Live quote
- Volume today (5,365) is well below its 3-month average of 1,228,470. (Finnhub fundamentals)
- Reports earnings on 2026-11-06, 15 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.03 actual vs. $-0.02 estimated (-47.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 6
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (9 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
XTNT
-61.35%
vs S&P 500
-74.13%
1-YEAR RETURN
XTNT
-60.14%
vs S&P 500
-74.70%
6-MONTH RETURN
XTNT
-37.53%
3-MONTH RETURN
XTNT
-31.89%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.03
Est. $-0.02
MISS -47.1%
2026-04-26 (Q1 2026)
$-0.02
Est. $-0.02
MISS -17.6%
2026-01-26 (Q4 2025)
$0.00
Est. $-0.01
BEAT +100.0%
2025-10-26 (Q3 2025)
$0.01
Est. $-0.01
BEAT +296.1%
Valuation Measures & Ratios
Enterprise Value4$62.3M
Forward P/E545.04
PEG Ratio6—
Price / Sales (TTM1)0.45
Price / Book71.48
EV4 / Revenue0.57
EV4 / EBITDA5.53
Profit Margin-10.17%
Operating Margin-6.59%
Return on Equity (ROE8)-23.45%
Return on Assets (ROA9)-12.44%
Avg Volume (3M)1,228,470
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $58.1M | $88.0M | $84.8M | $130.7M | — |
| P/E | -7.60 | 48.19 | -785.53 | -24.76 | — |
| Price/Sales | 0.52 | 0.72 | 0.66 | 1.04 | — |
| Price/Book | 1.45 | 1.81 | 1.68 | 2.69 | — |
| EV/Revenue | 0.53 | 0.72 | 0.71 | 1.16 | — |
| EV/EBITDA | -38.07 | 9.49 | 10.29 | — | — |
| ROE | -19.10% | 3.76% | -0.21% | -10.88% | — |
| ROA | -9.59% | 2.34% | -0.10% | -5.10% | — |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short143,564
Change from Prior Settlement-46.58%
% of Float—
Days to Cover (Short Ratio)1.00
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 4, filed 2026-08-18; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -35.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -10.2%. Finnhub fundamentals ↗
- Trailing 52-week price return is -60.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on XTNT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $23.0M | $20.9M | $33.3M | $35.4M | $32.9M | $27.9M | $29.9M | $27.9M |
| Gross profit | $13.3M | $12.0M | $22.0M | $24.3M | $20.2M | $16.3M | $18.6M | $17.3M |
| Operating income | -$9.2M | -$2.9M | $2.5M | $4.6M | $1.1M | -$3.8M | -$2.9M | -$3.5M |
| Net income | -$9.4M | -$3.1M | $1.3M | $3.5M | $58.0K | -$5.0M | -$3.9M | -$4.4M |
| EPS (diluted) | $-0.07 | $-0.02 | $0.01 | $0.02 | $0.00 | $-0.04 | $-0.03 | $-0.03 |
| EPS (basic) | $-0.07 | $-0.02 | $0.01 | $0.03 | $0.00 | $-0.04 | $-0.03 | $-0.03 |
| Operating margin | -$40 | -$14 | $8 | $13 | $3 | -$14 | -$10 | -$12 |
| Net margin | -$41 | -$15 | $4 | $10 | $0 | -$18 | -$13 | -$16 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $79.7M | $78.0M | $94.1M | $106.3M | $103.5M | $95.8M | $93.8M | $98.9M |
| Total liabilities | $39.7M | $29.4M | $43.2M | $55.9M | $55.0M | $52.0M | $50.9M | $53.2M |
| Stockholders' equity | $40.0M | $48.6M | $51.0M | $50.4M | $48.5M | $43.9M | $43.0M | $45.7M |
| Total current assets | $64.8M | $62.6M | $78.2M | $78.3M | $75.6M | $69.1M | $67.1M | $71.4M |
| Total current liabilities | $30.0M | $18.8M | $29.5M | $35.5M | $30.6M | $29.6M | $28.6M | $33.7M |
| Cash & equivalents | $9.9M | $12.1M | $17.1M | $10.4M | $6.9M | $5.0M | $6.2M | $6.6M |
| Accounts receivable | $19.4M | $17.2M | $17.8M | $25.5M | $27.0M | $23.5M | $20.7M | $20.5M |
| Inventory | $33.3M | $31.9M | $30.3M | $40.7M | $40.1M | $38.8M | $38.6M | $41.9M |
| Property, plant & equipment | $5.5M | $5.9M | $6.2M | $10.0M | $10.4M | $10.7M | $10.1M | $10.3M |
| Goodwill | $6.1M | $6.1M | $6.1M | $7.3M | $7.3M | $7.3M | $7.3M | $7.3M |
| Intangible assets | $252.0K | $275.0K | $299.0K | $7.1M | $7.5M | $7.9M | $8.4M | $8.8M |
| Other non-current assets | $128.0K | $131.0K | $133.0K | $1.0K | $15.0K | $1.0K | $103.0K | $103.0K |
| Accounts payable | $6.2M | $5.5M | $3.8M | $6.9M | $7.2M | $7.1M | $7.9M | $8.3M |
| Accrued liabilities | $7.5M | $8.5M | $10.6M | $11.5M | $10.6M | $10.5M | $7.8M | $8.9M |
| Short-term debt | $3.7M | $3.7M | $3.5M | — | — | — | — | $2.8M |
| Long-term debt | $7.3M | $8.1M | $11.0M | $17.4M | $22.3M | $22.2M | $22.0M | $19.1M |
| Other non-current liabilities | $5.0K | $5.0K | $5.0K | — | — | — | — | $38.0K |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$267.0M | -$257.6M | -$254.5M | -$254.5M | -$255.9M | -$259.4M | -$259.5M | -$256.3M |
| Accumulated other comprehensive income (loss) | -$1.0K | -$1.0K | — | $139.0K | $152.0K | -$209.0K | -$316.0K | $54.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.3M | -$2.1M | $5.4M | $4.6M | $1.3M | $1.3M | $665.0K | -$1.7M |
| Investing cash flow | -$5.2M | $10.2M | $4.7M | $4.7M | -$317.0K | -$1.1M | -$567.0K | -$2.0M |
| Financing cash flow | $10.6M | -$13.3M | -$3.5M | -$5.8M | $662.0K | -$919.0K | -$854.0K | $5.3M |
| Free cash flow | -$7.6M | -$2.3M | $5.0M | $4.2M | $910.0K | $87.0K | -$7.0K | -$3.8M |
| Capital expenditures | $247.0K | $194.0K | $395.0K | $430.0K | $366.0K | $1.2M | $672.0K | $2.1M |
| Depreciation & amortization | $508.0K | $534.0K | $1.8M | $1.2M | $1.2M | $1.1M | $1.1M | $1.1M |
| Share-based compensation | $875.0K | $746.0K | $1.4M | $600.0K | $766.0K | $758.0K | $3.2M | $1.1M |
| Deferred income taxes | — | — | -$38.0K | — | — | — | $21.0K | — |
| Change in accounts receivable | $2.5M | -$444.0K | -$5.0M | -$1.2M | $3.8M | $3.1M | $627.0K | -$560.0K |
| Change in inventory | $2.0M | $1.6M | -$790.0K | $1.4M | $814.0K | $535.0K | -$3.2M | $1.5M |
| Change in accounts payable | $668.0K | $1.6M | -$1.8M | -$399.0K | $10.0K | -$890.0K | -$257.0K | $1.3M |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | — | — | — | — | — | — | $0 | $0 |
| Debt repaid | $930.0K | $2.8M | $3.0M | $5.0M | — | — | — | $648.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M |
| Gross profit | $84.3M | $68.2M | $55.5M | $32.1M | $32.5M |
| Operating income | $7.3M | -$12.1M | -$10.2M | -$6.8M | -$3.9M |
| Net income | $5.0M | -$16.4M | $660.0K | -$8.5M | -$4.8M |
| EPS (diluted) | $0.03 | $-0.12 | $0.01 | $-0.09 | $-0.06 |
| EPS (basic) | $0.04 | $-0.12 | $0.01 | $-0.09 | $-0.06 |
| Operating margin | $5 | -$10 | -$11 | -$12 | -$7 |
| Net margin | $4 | -$14 | $1 | -$15 | -$9 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $94.1M | $93.8M | $92.6M | $60.2M | $54.7M |
| Total liabilities | $43.2M | $50.9M | $41.3M | $26.1M | $23.8M |
| Stockholders' equity | $51.0M | $43.0M | $51.3M | $34.2M | $30.9M |
| Total current assets | $78.2M | $67.1M | $64.9M | $49.3M | $44.3M |
| Total current liabilities | $29.5M | $28.6M | $23.0M | $15.2M | $11.1M |
| Cash & equivalents | $17.1M | $6.2M | $5.7M | $20.3M | $18.2M |
| Accounts receivable | $17.8M | $20.7M | $21.7M | $10.9M | $7.2M |
| Inventory | $30.3M | $38.6M | $36.9M | $17.3M | $17.9M |
| Property, plant & equipment | $6.2M | $10.1M | $8.7M | $5.8M | $5.2M |
| Goodwill | $6.1M | $7.3M | $7.3M | $3.2M | $3.2M |
| Intangible assets | $299.0K | $8.4M | $10.1M | $344.0K | $400.0K |
| Other non-current assets | $133.0K | $103.0K | $141.0K | $197.0K | $287.0K |
| Accounts payable | $3.8M | $7.9M | $7.1M | $3.5M | $2.6M |
| Accrued liabilities | $10.6M | $7.8M | $10.4M | $5.5M | $4.3M |
| Short-term debt | $3.5M | — | — | $2.3M | — |
| Long-term debt | $11.0M | $22.0M | $17.2M | $9.7M | $11.8M |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | -$254.5M | -$259.5M | -$243.0M | -$243.7M | -$235.2M |
| Accumulated other comprehensive income (loss) | — | -$316.0K | $29.0K | — | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $12.5M | -$11.9M | -$9.5M | -$5.3M | $439.0K |
| Investing cash flow | $7.9M | -$3.7M | -$24.8M | -$1.6M | -$1.9M |
| Financing cash flow | -$9.6M | $16.1M | $19.7M | $9.0M | $17.5M |
| Free cash flow | $10.2M | -$16.0M | -$11.0M | -$7.1M | -$1.7M |
| Capital expenditures | $2.4M | $4.1M | $1.5M | $1.8M | $2.1M |
| Depreciation & amortization | $5.2M | $4.2M | $3.2M | $1.3M | $1.3M |
| Share-based compensation | $2.9M | $4.1M | $2.7M | $2.5M | $2.2M |
| Deferred income taxes | -$38.0K | $21.0K | -$1.9M | — | — |
| Change in accounts receivable | $591.0K | $755.0K | $8.7M | $3.9M | $319.0K |
| Change in inventory | $2.0M | $2.5M | $1.9M | $1.2M | -$2.6M |
| Change in accounts payable | -$3.1M | $1.0M | $3.0M | $875.0K | -$332.0K |
| Purchases of investments | — | — | $17.0M | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | — | $5.0M | $5.0M | — | — |
| Debt repaid | $8.0M | — | — | — | $411.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding XTNT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-08-15 to 2026-08-15
Recent transactions
- Most recent: Lipschultz Tyler (Director) — Grant / award of 215,517 shares on 2026-08-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Lipschultz Tyler | Director | Grant / award | 2026-08-15 | 215,517 |
| BAKEWELL JOHN K | Director | Grant / award | 2026-08-15 | 215,517 |
| Beeson Jonn R. | Director | Grant / award | 2026-08-15 | 215,517 |
| JAIN ABHINAV | Director | Grant / award | 2026-08-15 | 215,517 |
| Vizirgianakis Stavros G. | Director | Grant / award | 2026-08-15 | 323,275 |
| Schallenberger Mark A. | Chief Operating Officer | Grant / award | 2026-08-15 | 450,000 |
| Neils Scott C | CFO and Assistant Secretary | Grant / award | 2026-08-15 | 400,000 |
| Browne Sean E | President and CEO | Grant / award | 2026-08-15 | 550,000 |
| ORBIMED ADVISORS LLC | 10% owner | Open market sale | 2025-04-10 | 56,004,974 |
| MITCHELL-KELLER LORI D | Director | Grant / award | 2024-08-15 | 162,162 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-15 | Lipschultz Tyler | Director | Grant / award | 215,517 | $0.00 |
| 2026-08-15 | BAKEWELL JOHN K | Director | Grant / award | 215,517 | $0.00 |
| 2026-08-15 | Beeson Jonn R. | Director | Grant / award | 215,517 | $0.00 |
| 2026-08-15 | JAIN ABHINAV | Director | Grant / award | 215,517 | $0.00 |
| 2026-08-15 | Vizirgianakis Stavros G. | Director | Grant / award | 323,275 | $0.00 |
| 2026-08-15 | Schallenberger Mark A. | Chief Operating Officer | Grant / award | 450,000 | $0.00 |
| 2026-08-15 | Schallenberger Mark A. | Chief Operating Officer | Tax withholding | 7,070 | $0.31 |
| 2026-08-15 | Neils Scott C | CFO and Assistant Secretary | Grant / award | 400,000 | $0.00 |
| 2026-08-15 | Neils Scott C | CFO and Assistant Secretary | Tax withholding | 28,155 | $0.31 |
| 2026-08-15 | Browne Sean E | President and CEO | Grant / award | 550,000 | $0.00 |
| 2026-08-15 | Browne Sean E | President and CEO | Tax withholding | 10,605 | $0.31 |
| 2026-02-15 | Schallenberger Mark A. | Chief Operating Officer | Tax withholding | 7,709 | $0.58 |
| 2026-01-15 | Neils Scott C | CFO and Assistant Secretary | Tax withholding | 8,084 | $0.65 |
| 2025-11-15 | Vizirgianakis Stavros G. | Director | Grant / award | 553,797 | $0.00 |
| 2025-11-15 | Beeson Jonn R. | Director | Grant / award | 158,228 | $0.00 |
| 2025-11-15 | BAKEWELL JOHN K | Director | Grant / award | 158,228 | $0.00 |
| 2025-11-15 | JAIN ABHINAV | Director | Grant / award | 158,228 | $0.00 |
| 2025-11-15 | Lipschultz Tyler | Director | Grant / award | 158,228 | $0.00 |
| 2025-11-15 | Browne Sean E | President and CEO | Grant / award | 394,937 | $0.00 |
| 2025-11-15 | Schallenberger Mark A. | Chief Operating Officer | Grant / award | 292,253 | $0.00 |
| 2025-11-15 | Neils Scott C | CFO and Assistant Secretary | Grant / award | 263,291 | $0.00 |
| 2025-08-15 | Browne Sean E | President and CEO | Tax withholding | 10,605 | $0.63 |
| 2025-08-15 | Neils Scott C | CFO | Tax withholding | 34,131 | $0.63 |
| 2025-04-10 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 56,004,974 | $0.42 |
| 2025-04-10 | ORBIMED ADVISORS LLC | 10% owner | Open market sale | 17,109,618 | $0.42 |
| 2025-01-15 | Neils Scott C | Chief Financial Officer | Tax withholding | 7,986 | $0.53 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:33 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-07 | 8-K | 2026-08-07 | View on SEC.gov → |
| 2026-05-13 | 10-Q | 2026-03-31 | View on SEC.gov → |
Recent news
Headlines about XTNT (Xtant Medical Holdings, Inc.). Links open the publisher — we don’t host full articles.
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2026-10-21 -
Xtant Medical Holdings stock trades at EUR 0.26 with USD 40.8 million market cap
AD HOC NEWS · 2026-10-20 -
Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market
Yahoo Finance · 2026-08-27 -
Xtant Medical Holdings Inc (XTNT) (Q2 2026) Earnings Call Highlights: Strategic Expansion Amid ...
Yahoo Finance · 2026-08-11 -
Xtant Medical Holdings, Inc. Q2 2026 Earnings Call Summary
Yahoo Finance · 2026-08-11 -
Xtant outlines $99M-$103M 2026 revenue guidance while integrating Dilon sales force
Seeking Alpha · 2026-08-11 -
Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-11 -
Xtant Medical Reports Second Quarter 2026 Financial Results
Yahoo Finance · 2026-08-11
No headlines in this category right now — try “All”.